Herpesviruses beyond HSV-1 and -2

Clinical Microbiology Newsletter

Volumn 21, Issue 19, 1999, Pages 153-159

  Arao, Yujiro ^a   Schmid, D Scott ^a   Pellett, Philip E ^a   Inoue, Naoki ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHICKENPOX VACCINE; CIDOFOVIR; CYTOMEGALOVIRUS VACCINE; EPSTEIN BARR VIRUS VACCINE; FOSCARNET; GANCICLOVIR; VALACICLOVIR;

CHICKENPOX; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; IMMUNE DEFICIENCY; LABORATORY DIAGNOSIS; REVIEW;

EID: 0033215533     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-4399(00)88241-0     Document Type: Article

References (43)

1. Fields, B.N. et al. (ed.). 1996. Fields Virology, 3rd Ed. Lippincott-Raven, Philadelphia.
2. Ahmed, R. and I.S.Y. Chen (ed.). 1999. Persistent Viral Infections. John Wiley & Sons, West Sussex, UK.
3. Lennette, E.H. et al. (ed.). 1995. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections, 7th Ed. American Public Health Association, Washington, DC.
4. Connor, D.H. et al. (ed.). 1997. Pathology of Infectious Diseases. Appleton & Lange, Stamford, CT.
5. Carlini, M. E. and W. X. Shandera. 1999. Infectious disease: Viral & rickettsial. In: L. M. Tierney et al. (ed.). Current Medical Diagnosis & Treatment 1999, 38th Ed. Appleton & Lange, Stamford, CT.
6. Patel, R. and C.V. Paya. 1997. Infections in solid-organ transplant recipients. Clin. Microbiol. Rev. 10:86-124.
7. Hillyer, C.D. et al. 1999. Transfusion of the HIV-seropositive patient: Immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. Transfusion Med. Rev. 13:1-17.
8. Braun, D.K., G. Dominguez, and P.E. Pellett. 1997. Human herpesvirus 6. Clin. Microbiol. Rev. 10:521-567.
9. Black, J.B. and P.E. Pellett. 1999. Human herpesvirus 7. Rev. Med. Virol. in press.
10. Wharton M. 1996. The epidemiology of varicella-zoster infections. Infect. Dis. Clin. N. Am. 10:571-581.
11. Davies, H.D. et al. 1996. Invasive group A streptococcal infections in Ontario, Canada: Ontario group A streptococcal study group. N. Engl. J. Med. 335:547-554.
12. Conn, R.B. et al. (ed.). 1997. Current Diagnosis. 9th Ed. W.B. Saunders Company, Philadelphia.
13. Boeckh, M. and G. Boivin. 1998. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications. Clin. Microbiol. Rev. 11:533-554.
14. Whitley, R.J. 1998. Antiviral therapy. p.330-350. In: S.L. Gorbach et al. (ed.). Infectious Diseases, 2nd Ed. W.B. Saunders Company, Philadelphia.
15. Martin, D.F. et al. 1999. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N. Engl. J. Med. 340:1063-1070.
16. Sepkowitz, K.A. 1998. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 351:228-230.
17. Heslop, H.E. and C.M. Rooney. 1997. Adoptive cellular immunotherapy for EBV lymphoproliferative diseases. Immunol.Rev. 157:217-222.
18. Riddle, S.R. and P.D. Greenberg. 1997. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev. Med. Virol. 7:181-192.
19. Benkerrou, M. et al. 1998. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 92:3137-3147.
20. Centers for Disease Control and Prevention. 1999. USPHS/IDSA/ ASBMT guidelines for the prevention of opportunistic infections (OIs) in bone marrow transplant (BMT) recipients. MMWR, in press.
21. Centers for Disease Control and Prevention. 1999. USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. MMWR, in press.
22. Centers for Disease Control and Prevention. 1996. Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (Acip). MMWR 45(RR-11):1-36.
23. Centers for Disease Control and Prevention. 1999. Prevention of Varicella Updated Recommendations of the Advisory Committee on Immunization Practices (Acip). MMWR 48(RR-06): 1-5.
24. Gershon, A.A. 1995. Varicella-zoster virus: Prospects for control. Adv. Pediatr. Infect. Dis. 10:93-124.
25. LaRussa, P. et al. 1998. Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. J. Infect. Dis. 178 (Suppl 1): S64-66.
26. Plotkin, S.A. 1999. Vaccination against cytomegalovirus, the changing demon. Pediatr. Infect. Dis. J. 18:313-326.
27. Finerty, S. et al. 1992. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J. Gen. Virol. 73:449-453.
28. Gu, S.Y. et al. 1995. First EBV vaccine trial in human using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand. 84:171-177.
29. Osato, T. and S. Imai. 1996. Epstein-Barr virus and gastric carcinoma. Semin. Cancer Biol. 7:175-182.
30. Nishikawa, J. et al. 1999. Epstein-Barr virus promotes epithelial cell growth in the absence of EBNA2 and LMP1 expression. J. Virol. 73:1286-1292.
31. High, K.P. 1999. Atherosclerosis and infection due to Chlamydia pneumoniae or cytomegalovirus: Weighing the evidence. Clin. Infect. Dis. 28:746-749.
32. Danesh, J., R. Collins, and R. Peto. 1997. Chronic infections and coronary heart disease: Is there a link? Lancet 350:430-436.
33. Speir, E., Z.-X. Yu, and V.J. Ferrans. 1998 Infectious agents in coronary artery disease: Viral infection, aspirin, and gene expression in human coronary smooth muscle cells. Rev. Port. Cardiol. 17(suppl II):33-39.
34. Wilborn, F. et al. 1994. A potential role for human herpesvirus type 6 in nervous system disease. J. Neuroimmunol. 4:213-214.
35. Challoner, P.B. et al. 1995. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc. Natl. Acad. Sci. USA 92:7440-7444.
36. Soldan, S.S. et al. 1997. Association of human herpesvirus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Med. 3:1394-1397.
37. Drago, F. et al. 1997. Human herpesvirus 7 in pityriasis rosea. Lancet 349:1367-1368.
38. Rettig, M.B. et al. 1997. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851-1854.
39. Said, J.W. et al. 1997. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood 90:4278-4282.
40. Parravicini, C. et al. 1997. Technical comments. Science 278:1969-1973.
41. Gao, S.-J. et al. 1998. Antibodies to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in patients with multiple myeloma. J. Infect. Dis. 178:846-849.
42. Masala, G. et al. 1996. Incidence rates of leukemias, lymphomas and myelomas in Italy: Geographic distribution and NHL histotypes. Int. J. Cancer 68:156-159.
43. Cannon, M.J., W.D. Flanders, and P.E. Pellett. Occurrence of primary cancers in association with multiple myeloma and Kaposi's sarcoma in the United States, 1973-1995. Int. J. Cancer, in press.